WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
- Jefferies London Healthcare Conference
November 14, 2018 at 9:40 am ET/2:40 pm GMT
- Evercore ISI HealthConX
November 27, 2018 at 8:45 am ET
- 30th Annual Piper Jaffray Healthcare Conference
November 28, 2018 at 11:30 am ET
A webcast of each presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005288/en/
Source: ImmunoGen, Inc.
INVESTOR RELATIONS CONTACT
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com
or
THRUST Strategic Communications
Chelcie Lister, 910-777-3049
chelcie@thrustsc.com
or
MEDIA CONTACT
ImmunoGen, Inc.
Courtney O’Konek, 781-895-0600
courtney.okonek@immunogen.com
or
FTI Consulting
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
